PT2235017E - Derivados de espirolidona como agentes contra o cancro - Google Patents
Derivados de espirolidona como agentes contra o cancro Download PDFInfo
- Publication number
- PT2235017E PT2235017E PT08863724T PT08863724T PT2235017E PT 2235017 E PT2235017 E PT 2235017E PT 08863724 T PT08863724 T PT 08863724T PT 08863724 T PT08863724 T PT 08863724T PT 2235017 E PT2235017 E PT 2235017E
- Authority
- PT
- Portugal
- Prior art keywords
- anticancer agents
- spiroindolinone derivatives
- spiroindolinone
- derivatives
- agents
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1488807P | 2007-12-19 | 2007-12-19 | |
| US10738108P | 2008-10-22 | 2008-10-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2235017E true PT2235017E (pt) | 2011-10-13 |
Family
ID=40351961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08863724T PT2235017E (pt) | 2007-12-19 | 2008-12-09 | Derivados de espirolidona como agentes contra o cancro |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7776875B2 (pt) |
| EP (1) | EP2235017B1 (pt) |
| JP (1) | JP2011506524A (pt) |
| KR (1) | KR20100076075A (pt) |
| CN (1) | CN101903388A (pt) |
| AT (1) | ATE524470T1 (pt) |
| AU (1) | AU2008340473A1 (pt) |
| BR (1) | BRPI0820699A2 (pt) |
| CA (1) | CA2708312A1 (pt) |
| DK (1) | DK2235017T3 (pt) |
| ES (1) | ES2372903T3 (pt) |
| IL (1) | IL205506A0 (pt) |
| MX (1) | MX2010006332A (pt) |
| PL (1) | PL2235017T3 (pt) |
| PT (1) | PT2235017E (pt) |
| WO (1) | WO2009080488A1 (pt) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100190814A1 (en) * | 2009-01-26 | 2010-07-29 | Li Chen | Spiroindolinone derivative prodrugs |
| US8217051B2 (en) | 2009-02-17 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US8076482B2 (en) * | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| AU2010319595B2 (en) * | 2009-11-12 | 2015-09-17 | The Regents Of The University Of Michigan | Spiro-oxindole MDM2 antagonists |
| US8088815B2 (en) | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8288431B2 (en) | 2010-02-17 | 2012-10-16 | Hoffmann-La Roche Inc. | Substituted spiroindolinones |
| US8217044B2 (en) | 2010-04-28 | 2012-07-10 | Hoffmann-La Roche Inc. | Spiroindolinone pyrrolidines |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US8680132B2 (en) | 2010-11-12 | 2014-03-25 | The Regents Of The University Of Michigan | Spiro-oxindole MDM2 antagonists |
| RS57158B1 (sr) * | 2011-03-10 | 2018-07-31 | Daiichi Sankyo Co Ltd | Dispiropirolidinski derivat |
| US8629141B2 (en) | 2011-05-11 | 2014-01-14 | The Regents Of The University Of Michigan | Spiro-oxindole MDM2 antagonists |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| PL3738434T3 (pl) | 2011-12-28 | 2024-03-04 | Global Blood Therapeutics, Inc. | Związki pośrednie do otrzymywania podstawionych związków benzaldehydowych i sposoby ich zastosowania do zwiększania natlenienia tkanek |
| CN102838610B (zh) * | 2012-08-28 | 2014-09-10 | 吕叶叶 | 双吲哚二氧杂双环辛二酮 |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| CA2902856C (en) | 2013-02-28 | 2021-02-16 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| WO2014145040A1 (en) * | 2013-03-15 | 2014-09-18 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
| US9802900B2 (en) | 2013-03-15 | 2017-10-31 | Global Blood Therapeutics, Inc. | Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin |
| CN105073728A (zh) | 2013-03-15 | 2015-11-18 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US9604999B2 (en) | 2013-03-15 | 2017-03-28 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| KR20190041548A (ko) | 2013-03-15 | 2019-04-22 | 글로벌 블러드 테라퓨틱스, 인크. | 헤모글로빈 조정을 위한 화합물 및 이의 용도 |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| PE20160179A1 (es) | 2014-02-07 | 2016-05-20 | Global Blood Therapeutics Inc | Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)piridin-3-il)metoxi)benzaldehido |
| JP6503386B2 (ja) | 2014-07-03 | 2019-04-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＭＤＭ２−ｐ５３阻害剤としての新しいスピロ［３Ｈ−インドール−３，２’−ピロリジン］−２（１Ｈ）−オン化合物および誘導体 |
| EP3260119B1 (en) | 2015-02-20 | 2023-11-15 | Daiichi Sankyo Company, Limited | Combination method for treating cancer |
| MA41841A (fr) | 2015-03-30 | 2018-02-06 | Global Blood Therapeutics Inc | Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs |
| US10485794B2 (en) | 2015-04-13 | 2019-11-26 | Daiichi Sankyo Company, Limited | Treatment method by combined use of MDM2 inhibitor and BTK inhibitor |
| CA3000063A1 (en) | 2015-10-09 | 2017-04-13 | Boehringer Ingelheim International Gmbh | Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors |
| TW201731509A (zh) | 2015-12-04 | 2017-09-16 | 全球血液治療公司 | 針對２-羥基-６-（（２-（１-異丙基-１ｈ-吡唑-５-基）吡啶-３-基）甲氧基）-苯甲醛之劑量方案 |
| AR108435A1 (es) | 2016-05-12 | 2018-08-22 | Global Blood Therapeutics Inc | Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído |
| CN109152843A (zh) | 2016-05-20 | 2019-01-04 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| TWI778983B (zh) | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| EP3527226A4 (en) | 2016-10-17 | 2020-06-17 | Daiichi Sankyo Company, Limited | POLYTHERAPY METHOD USING MDM2 INHIBITOR AND DNA METHYLTRANSFERASE INHIBITOR |
| EP3511334A1 (en) * | 2018-01-16 | 2019-07-17 | Adamed sp. z o.o. | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-c]pyrrole]-2,3'-dione compounds as therapeutic agents activating tp53 |
| WO2020072377A1 (en) | 2018-10-01 | 2020-04-09 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin for the treatment of sickle cell disease |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| CN117069647A (zh) * | 2023-07-27 | 2023-11-17 | 兰州大学 | 一种双官能团螺环催化剂及其合成方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE200200033A (et) * | 1999-07-21 | 2003-02-17 | Astrazeneca Ab | Uued ühendid |
| EP1856123B1 (en) * | 2005-02-22 | 2016-02-17 | The Regents Of The University Of Michigan | Small molecule inhibitors of mdm2 and uses thereof |
| EP1911753A1 (en) * | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| US20070213341A1 (en) * | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| US7495007B2 (en) * | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| EP1996591B1 (en) * | 2006-03-13 | 2011-01-12 | F. Hoffmann-La Roche AG | Spiroindolinone derivatives |
| US7784589B2 (en) * | 2006-07-10 | 2010-08-31 | Inventio Ag | Elevator lift cage load measuring assembly |
| US7638548B2 (en) * | 2006-11-09 | 2009-12-29 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US7834179B2 (en) * | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| US8134001B2 (en) * | 2007-12-14 | 2012-03-13 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
-
2008
- 2008-11-18 US US12/273,035 patent/US7776875B2/en not_active Expired - Fee Related
- 2008-12-09 AT AT08863724T patent/ATE524470T1/de active
- 2008-12-09 MX MX2010006332A patent/MX2010006332A/es active IP Right Grant
- 2008-12-09 ES ES08863724T patent/ES2372903T3/es active Active
- 2008-12-09 JP JP2010538565A patent/JP2011506524A/ja active Pending
- 2008-12-09 CN CN2008801217831A patent/CN101903388A/zh active Pending
- 2008-12-09 BR BRPI0820699A patent/BRPI0820699A2/pt not_active IP Right Cessation
- 2008-12-09 PT PT08863724T patent/PT2235017E/pt unknown
- 2008-12-09 EP EP08863724A patent/EP2235017B1/en not_active Not-in-force
- 2008-12-09 WO PCT/EP2008/067061 patent/WO2009080488A1/en active Application Filing
- 2008-12-09 CA CA2708312A patent/CA2708312A1/en not_active Abandoned
- 2008-12-09 DK DK08863724.4T patent/DK2235017T3/da active
- 2008-12-09 KR KR1020107013353A patent/KR20100076075A/ko active IP Right Grant
- 2008-12-09 PL PL08863724T patent/PL2235017T3/pl unknown
- 2008-12-09 AU AU2008340473A patent/AU2008340473A1/en not_active Abandoned
-
2010
- 2010-05-03 IL IL205506A patent/IL205506A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2708312A1 (en) | 2009-07-02 |
| US7776875B2 (en) | 2010-08-17 |
| CN101903388A (zh) | 2010-12-01 |
| EP2235017A1 (en) | 2010-10-06 |
| AU2008340473A1 (en) | 2009-07-02 |
| JP2011506524A (ja) | 2011-03-03 |
| PL2235017T3 (pl) | 2012-02-29 |
| EP2235017B1 (en) | 2011-09-14 |
| IL205506A0 (en) | 2010-12-30 |
| MX2010006332A (es) | 2010-07-05 |
| KR20100076075A (ko) | 2010-07-05 |
| ES2372903T3 (es) | 2012-01-27 |
| ATE524470T1 (de) | 2011-09-15 |
| DK2235017T3 (da) | 2011-10-24 |
| BRPI0820699A2 (pt) | 2019-09-24 |
| WO2009080488A1 (en) | 2009-07-02 |
| US20090163512A1 (en) | 2009-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL205506A0 (en) | Spiroindolinone derivatives as anticancer agents | |
| IL205354A0 (en) | Spiroindolinone derivatives | |
| IL193620A0 (en) | Spiroindolinone derivatives | |
| TW200801000A (en) | Spiroindolinone derivatives | |
| MY160424A (en) | Substituted pyrrolidine-2-carboxyamides. | |
| MX2011008176A (es) | Derivados de 3,3'-espiroindolinona como agentes anticancerigenos. | |
| MX2012009186A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| IN2012DN02487A (pt) | ||
| MX2011007886A (es) | Derivado de espiroindolinona piridina. | |
| MY160596A (en) | Spiroindolinone pyrrolidines | |
| MX2014014229A (es) | Pirrolidina-2-carboxamidas sustituidas. | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| WO2009057079A3 (en) | Novel pyrimidine derivatives | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| MY156319A (en) | Spiroheterocyclic n-oxypiperidines as pesticides | |
| TW200740758A (en) | Benzoquinazoline derivatives | |
| IL197197A0 (en) | Oxindole derivatives as anticancer agents | |
| WO2007084728A3 (en) | 2-imino-benzimidazoles | |
| TW200738695A (en) | Cis-4,5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors | |
| MY147188A (en) | Substituted imidazole compounds as ksp inhibitors | |
| IL208025A0 (en) | Spiroindolinone derivatives | |
| EP2581372A4 (en) | CYANOCHINOLINDERIVATE | |
| TNSN08369A1 (en) | Benzimidazole derivatives | |
| EP2578587A4 (en) | PYRAZOLE DERIVATIVES | |
| GB201305247D0 (en) | Amide Compounds |